We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-6.51%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.59B
AUM Growth
-$241M
Cap. Flow
-$119M
Cap. Flow %
-7.49%
Top 10 Hldgs %
53.34%
Holding
89
New
20
Increased
22
Reduced
13
Closed
28

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$50.3M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$41.3M
3
LOW icon
Lowe's Companies
LOW
+$36.2M
4
UTHR icon
United Therapeutics
UTHR
+$30.3M
5
RH icon
RH
RH
+$23.1M

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$40.8M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$37.9M
3
AZO icon
AutoZone
AZO
+$28.7M
4
BIIB icon
Biogen
BIIB
+$28.2M
5
PLYA
Playa Hotels & Resorts
PLYA
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 31.87%
2 Consumer Discretionary 15.3%
3 Industrials 5.59%
4 Consumer Staples 4.92%
5 Technology 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRS
26
DELISTED
Antares Pharma, Inc.
ATRS
$19.7M 1.24%
6,000,000
-4,300,000
-42% -$12.4M
DPLO
27
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$19.5M 1.23%
3,200,000
+200,000
+7% +$1.06M
INCY icon
28
Incyte
INCY
$26.4B
$19.4M 1.22%
+228,000
New +$18.3M
CPRX
29
DELISTED
Catalyst Pharmaceutical
CPRX
$19.2M 1.21%
5,000,000
+3,480,000
+229% +$15M
PLNT icon
30
Planet Fitness
PLNT
$4.41B
$19.1M 1.21%
+264,000
New +$19.9M
ADMS
31
DELISTED
Adamas Pharmaceuticals
ADMS
$16.7M 1.06%
2,700,000
-44,000
-2% -$253K
QSR icon
32
Restaurant Brands International
QSR
$26B
$12.7M 0.8%
+183,000
New +$12.3M
BLUE
33
DELISTED
bluebird bio
BLUE
$12.7M 0.8%
7,720
+2,470
+47% +$4.27M
CLLS
34
Cellectis
CLLS
$285M
$12.5M 0.79%
800,000
+72,000
+10% +$1.29M
JACK icon
35
Jack in the Box
JACK
$310M
$12.2M 0.77%
150,000
+30,000
+25% +$2.42M
PRTK
36
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$9.89M 0.62%
2,478,000
+354,000
+17% +$1.68M
LULU icon
37
lululemon athletica
LULU
$13.6B
$9.73M 0.61%
+54,000
New +$9.38M
KMX icon
38
CarMax
KMX
$8.25B
$9.55M 0.6%
+110,000
New +$8.6M
GOOS
39
Canada Goose Holdings
GOOS
$902M
$8.44M 0.53%
+218,000
New +$9.81M
TGT icon
40
Target
TGT
$65.5B
$8.05M 0.51%
93,000
-307,000
-77% -$24.8M
SKX
41
DELISTED
Skechers
SKX
$7.93M 0.5%
+252,000
New +$7.78M
AMZN icon
42
Amazon
AMZN
$2.49T
$7.58M 0.48%
80,000
– –
SPOT icon
43
Spotify
SPOT
$105B
$7.02M 0.44%
48,000
+8,000
+20% +$1.1M
BHVN
44
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.01M 0.44%
+160,000
New +$9.02M
ONCE
45
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$6.96M 0.44%
+68,000
New +$7.34M
BIIB icon
46
Biogen
BIIB
$30.1B
$6.55M 0.41%
28,000
-122,000
-81% -$28.2M
FL
47
DELISTED
Foot Locker
FL
$6.29M 0.4%
+150,000
New +$7.8M
ALIM
48
DELISTED
Alimera Sciences
ALIM
$5.19M 0.33%
389,067
-73,333
-16% -$1.03M
SBBP
49
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.95M 0.31%
1,580,000
-912,000
-37% -$3.35M
KPRX icon
50
Kiora Pharmaceuticals
KPRX
$11.2M
$4.28M 0.27%
3,299
– –
1
2
3 4

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Armistice Capital held 89 positions worth $1.59B, down 13% from $1.83B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Armistice Capital withdrew a net $119M in Q2 2019, closing 28 positions and reducing 13 holdings. Its most notable exit was Pacira BioSciences, an estimated $40.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 36% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Armistice Capital opened a new position in Vanda Pharmaceuticals worth $44.5M.

  • Armistice Capital's largest Q2 2019 buy was Vanda Pharmaceuticals: 3,158,000 shares worth $44.5M.
  • Armistice Capital added most to Edgewell Personal Care in Q2 2019, an estimated $20.3M increase.
  • Armistice Capital's biggest Q2 2019 reduction was Biogen, cutting an estimated $28.2M.
  • Armistice Capital fully exited Pacira BioSciences in Q2 2019, selling an estimated $40.8M.
  • Armistice Capital's ten largest holdings make up 53% of its $1.59B portfolio in Q2 2019.
  • Armistice Capital opened 20 new positions and closed 28 in Q2 2019.
  • Armistice Capital's portfolio value fell 13% quarter-over-quarter to $1.59B.

Based on Armistice Capital's 13F filing for Q2 2019, filed 14 Aug 2019.